<i>“Why has this new vaccine come and for what reasons?”</i> key antecedents and questions for acceptance of a future maternal GBS vaccine: Perspectives of pregnant women, lactating women, and community members in Kenya-Reference-Cited by-同舟云学术

“Why has this new vaccine come and for what reasons?” key antecedents and questions for acceptance of a future maternal GBS vaccine: Perspectives of pregnant women, lactating women, and community members in Kenya

Published:2024-02-12 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Limaye Rupali J.¹^ORCID,Singh Prachi²,Fesshaye Berhaun²,Lee Clarice²,Schue Jessica²,Karron Ruth A.³

Affiliation:

1. Department of International Health, Department of Epidemiology, Department of Health, Behavior & Society, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

2. Department of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

3. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Funder

Bill and Melinda Gates Foundation

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2314826

Reference28 articles.

1. Group B streptococcal disease in the mother and newborn—A review

2. The Double Life of Group B Streptococcus: Asymptomatic Colonizer and Potent Pathogen

3. Group B streptococcus vaccine. [accessed 2023 Sep 14]. https://www.who.int/publications-detail-redirect/9789240037526.

4. Maternal colonization with Streptococcus agalactiae and associated stillbirth and neonatal disease in coastal Kenya

5. 20 million pregnant women with group B streptococcus carriage: consequences, challenges, and opportunities for prevention